<li>aceclofenac<p>aceclofenac, alendronate.
Either increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of GI ulceration.</p></li><li>acemetacin<p>acemetacin, alendronate.
Either increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of GI ulceration.</p></li><li>aspirin<p>aspirin, alendronate.
Either increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of GI ulceration.</p></li><li>aspirin rectal<p>aspirin rectal, alendronate.
Either increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of GI ulceration.</p></li><li>aspirin/citric acid/sodium bicarbonate<p>aspirin/citric acid/sodium bicarbonate, alendronate.
Either increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of GI ulceration.</p></li><li>celecoxib<p>celecoxib, alendronate.
Either increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of GI ulceration.</p></li><li>choline magnesium trisalicylate<p>choline magnesium trisalicylate, alendronate.
Either increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of GI ulceration.</p></li><li>diclofenac<p>diclofenac, alendronate.
Either increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of GI ulceration.</p></li><li>diflunisal<p>diflunisal, alendronate.
Either increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of GI ulceration.</p></li><li>etodolac<p>etodolac, alendronate.
Either increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of GI ulceration.</p></li><li>etoricoxib<p>etoricoxib, alendronate.
Either increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of GI ulceration.</p></li><li>famotidine<p>famotidine increases levels of alendronate by unspecified interaction mechanism. Minor/Significance Unknown. Monitor for increase in alendronate side effects.</p></li><li>fenbufen<p>fenbufen, alendronate.
Either increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of GI ulceration.</p></li><li>fenoprofen<p>fenoprofen, alendronate.
Either increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of GI ulceration.</p></li><li>flurbiprofen<p>flurbiprofen, alendronate.
Either increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of GI ulceration.</p></li><li>foscarnet<p>foscarnet increases effects of alendronate by pharmacodynamic synergism. Minor/Significance Unknown. Risk of severe hypocalcemia.</p></li><li>ibuprofen<p>ibuprofen, alendronate.
Either increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of GI ulceration.</p></li><li>indomethacin<p>indomethacin, alendronate.
Either increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of GI ulceration.</p></li><li>ketoprofen<p>ketoprofen, alendronate.
Either increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of GI ulceration.</p></li><li>ketorolac<p>ketorolac, alendronate.
Either increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of GI ulceration.</p></li><li>ketorolac intranasal<p>ketorolac intranasal, alendronate.
Either increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of GI ulceration.</p></li><li>levothyroxine<p>levothyroxine decreases levels of alendronate by unspecified interaction mechanism. Minor/Significance Unknown. Bioavailability of alendronate decreases slightly.</p></li><li>lornoxicam<p>lornoxicam, alendronate.
Either increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of GI ulceration.</p></li><li>meclofenamate<p>meclofenamate, alendronate.
Either increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of GI ulceration.</p></li><li>mefenamic acid<p>mefenamic acid, alendronate.
Either increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of GI ulceration.</p></li><li>meloxicam<p>meloxicam, alendronate.
Either increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of GI ulceration.</p></li><li>nabumetone<p>nabumetone, alendronate.
Either increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of GI ulceration.</p></li><li>naproxen<p>naproxen, alendronate.
Either increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of GI ulceration.</p></li><li>oxaprozin<p>oxaprozin, alendronate.
Either increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of GI ulceration.</p></li><li>parecoxib<p>parecoxib, alendronate.
Either increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of GI ulceration.</p></li><li>piroxicam<p>piroxicam, alendronate.
Either increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of GI ulceration.</p></li><li>ranitidine<p>ranitidine increases levels of alendronate by unknown mechanism. Minor/Significance Unknown. Interaction seen with IV ranitidine.</p></li><li>salicylates (non-asa)<p>salicylates (non-asa), alendronate.
Either increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of GI ulceration.</p></li><li>salsalate<p>salsalate, alendronate.
Either increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of GI ulceration.</p></li><li>sulfasalazine<p>sulfasalazine, alendronate.
Either increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of GI ulceration.</p></li><li>sulindac<p>sulindac, alendronate.
Either increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of GI ulceration.</p></li><li>teriparatide<p>teriparatide, alendronate. Other (see comment). Minor/Significance Unknown. 
Comment: No advantage to bone density with combined treatment.</p></li><li>tolfenamic acid<p>tolfenamic acid, alendronate.
Either increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of GI ulceration.</p></li><li>tolmetin<p>tolmetin, alendronate.
Either increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of GI ulceration.</p></li>